20 articles
Researchers develop standardized lung washing procedure that rapidly improves breathing and quality of life in patients with rare disease.
Combining targeted therapies may help patients with severe hidradenitis suppurativa who don't respond to standard treatments.
A newly identified immune axis involving CD16+ ฮณฮด T cells and antibody-dependent killing may reshape how we understand HBV immune control.
A completed RCT tests whether 1-hour pathogen detection paired with antimicrobial stewardship slashes broad-spectrum antibiotic days in HAP patients.
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
Revolutionary cancer treatment successfully treats treatment-resistant autoimmune disease, offering hope for severe cases.
New research reveals mortality from this rare immune disorder varies by time, potentially improving treatment strategies.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
A new WHO public health emergency declaration over Bundibugyo Ebola raises urgent questions about health equity and international pandemic preparedness.
A German proof-of-concept trial tests whether a maximal five-class antiretroviral regimen can deplete latent HIV reservoirs.
Breakthrough treatments targeting specific immune pathways show promise for reducing steroid dependence in EGPA patients.
A pilot study finds one 30-minute PAPIMI electromagnetic field session significantly reduced pain scores and raised parasympathetic HRV markers in chronic musculoskeletal pain patients.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
65 neurologists from 54 Italian MS centers agree on when and how to use high-efficacy therapies to prevent irreversible disability.
A novel biologic targeting IL-33 shows promising advances in COPD treatment, potentially reshaping how chronic lung disease is managed.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
New research reveals how where you live dramatically affects your ability to receive proper care for psoriatic arthritis.
